Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.64 |
| ▸ | MAOA | P21397 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 2/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1547975 | 0.91 | MAOB (0.74) | MAOBMAOAFFAR1F2IDO1 | |
| SCHEMBL15344203 | 0.88 | MAOB (0.80) | MAOBMAOAFFAR1NR1H4IDO1 | |
| SCHEMBL14437517 | 0.83 | MAOB (0.66) | MAOBMAOAFFAR1NR1H4IDO1 | |
| SCHEMBL27515340 | 0.83 | MAOB (0.64) | MAOBMAOAFFAR1NR1H4MEN1 | |
| SCHEMBL30398600 | 0.83 | MAOB (0.66) | MAOBMAOAFFAR1NR1H4IDO1 | |
| SCHEMBL15474264 | 0.83 | FFAR1 (0.58) | MAOBMAOATSHRSMN1; SMN2FFAR1 | |
| SCHEMBL685837 | 0.82 | MAOB (0.68) | MAOBMAOACYP4F2CYP4A11MEN1 | |
| SCHEMBL28893553 | 0.82 | TSHR (0.59) | MAOBTSHRSMN1; SMN2FFAR1F2 | |
| SCHEMBL29961933 | 0.82 | TSHR (0.59) | MAOBTSHRSMN1; SMN2FFAR1F2 | |
| SCHEMBL1549250 | 0.82 | MAOB (0.68) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190269785-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2019-09-05 | — | — | US | disclosed |
| US-10201614-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS INC. | 2019-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10201614-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, CCNB2 | MAOB 3101/4885MAOA 3266/4885TSHR 4625/4885 |
| US-20190269785-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | MAOB 3060/4885MAOA 3194/4885TSHR 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.